THE INVESTOR

메뉴열기
July 18, 2018

Humedix gets approval for salmon-based wound healing booster

PUBLISHED : April 16, 2018 - 16:13

UPDATED : April 16, 2018 - 16:13

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

[THE INVESTOR] Humedix, a subsidiary of Huons Global, said on April 16 that it has obtained sales approval for two types of injection therapies that repair damaged skin and encourage wound healing.

The products -- Revitalrex and Revitalrex prefilled syringe -- are based on Polydeoxyribonucleotide, or PDRN, which is extracted from salmon trout sperm and is being used for cell regeneration in various medical fields including dermatology. 


Humedix headquarters



“Revitalrex is a key product that will lead Humedix’s mid- to long-term growth. We plan to expand our portfolio to aesthetics sector including skin care and cosmetic medical devices as well as arthritis treatment,” said Humedix CEO Jung Gu-wan in a statement.

With the approval, Humedix is beefing up its pipeline mainly depended on hyaluronic acid injections for rheumatoid arthritis and dermal fillers.

By Park Han-na (hnpark@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.